| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -36,200 | -17,730 | -26,170 | -28,320 | -36,230 |
| Net Income Growth | -104.17% | +32.25% | +7.59% | +21.83% | -20.41% |
Biomx Ltd (PHGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC and cancer. BiomX Ltd, formerly known as Chardan Healthcare Acquisition Corp., is based in Ness Ziona, Israel.
Fiscal Year End Date: 12/31